| Value | ₹16,982 Cr |
|---|
NSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,300.00
- Market cap
- ₹64,912 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.1×Sector 46.1×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Other results update announcements
All →Zensar Technologies Results Update
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.
Dodla Dairy Results Update
Dodla Dairy's press release shows Q2 FY27 revenue up 17.4% but PAT down 44.3%. It also flags a proposed 40% stake in a joint venture with MIHL.
Fabtech Technologies Results Update
Fabtech released Q2 FY27 consolidated highlights, with revenue and profit down year-on-year. Management expects H2 execution to step up and targets an 8–9% PAT margin.
Creative Newtech Results Update
Creative Newtech reported Q2 FY27 standalone total income of Rs.664.55 Crore, with PAT up 78.43% YoY to Rs.12.65 Crore. The media release also covers consolidated results and recent acquisition and partnership developments.
ACME Solar Holdings Results Update
ACME Solar reported Q2 FY27 consolidated EBITDA of INR 874 Cr and PAT of INR 269 Cr. Both rose sharply year-on-year on BESS and RE capacity additions.
IIFL Capital Services Results Update
IIFL Capital Services reported consolidated Q2FY27 revenue of ₹722 crore, up 22% year-on-year, with PBT of ₹174 crore. The press release also covers the Fairfax change-in-control and a proposed NBFC subsidiary.